Atorvastatin lowers breast cancer risk by reversing an early tumorigenic signature.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
received:
31
01
2024
accepted:
15
07
2024
medline:
2
8
2024
pubmed:
2
8
2024
entrez:
1
8
2024
Statut:
epublish
Résumé
Breast cancer remains a significant health challenge with complex molecular mechanisms. While many studies have explored genetic markers in breast carcinogenesis, few have studied the potential impact of pharmacological interventions such as Atorvastatin on its genetic landscape. This study aimed to elucidate the molecular distinctions between normal and tumor-adjacent tissues in breast cancer and to investigate the potential protective role of atorvastatin, primarily known for its lipid-lowering effects, against breast cancer. Searching the Gene Expression Omnibus database identified two datasets, GSE9574 and GSE20437, comparing normal breast tissues with tumor-adjacent samples, which were merged, and one dataset, GSE63427, comparing paired pre- and post-treated patients with atorvastatin. Post-ComBat application showed merged datasets' consistency, revealing 116 DEGs between normal and tumor-adjacent tissues. Although initial GSE63427 data analysis suggested a minimal impact of atorvastatin, 105 DEGs post-treatment were discovered. Thirteen genes emerged as key players, both affected by Atorvastatin and dysregulated in tumor-adjacent tissues. Pathway analysis spotlighted the significance of these genes in processes like inflammation, oxidative stress, apoptosis, and cell cycle control. Moreover, there was a noticeable interaction between these genes and the immunological microenvironment in tumor-adjacent tissues, with Atorvastatin potentially altering the suppressive immune landscape to favor anti-tumor immunity. Survival analysis further highlighted the prognostic potential of the 13-gene panel, with 12 genes associated with improved survival outcomes. The 13-gene signature offers promising insights into breast cancer's molecular mechanisms and atorvastatin's potential therapeutic role. The preliminary findings advocate for an in-depth exploration of atorvastatin's impact on.
Identifiants
pubmed: 39090164
doi: 10.1038/s41598-024-67706-2
pii: 10.1038/s41598-024-67706-2
doi:
Substances chimiques
Atorvastatin
A0JWA85V8F
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
17803Informations de copyright
© 2024. The Author(s).
Références
Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7–33 (2022).
pubmed: 35020204
doi: 10.3322/caac.21708
la Mare, J.-A. et al. Breast cancer: Current developments in molecular approaches to diagnosis and treatment. Recent Patents Anticancer Drug Discov. 9, 153–175 (2014).
doi: 10.2174/15748928113086660046
Waks, A. G. & Winer, E. P. Breast cancer treatment: A review. JAMA 321, 288–300 (2019).
pubmed: 30667505
doi: 10.1001/jama.2018.19323
Pondé, N. F., Zardavas, D. & Piccart, M. Progress in adjuvant systemic therapy for breast cancer. Nat. Rev. Clin. Oncol. 16, 27–44 (2019).
pubmed: 30206303
doi: 10.1038/s41571-018-0089-9
Ma, L. Determinants of breast cancer progression. Sci. Transl. Med. 6, 243fs25 (2014).
pubmed: 24990878
pmcid: 4157363
doi: 10.1126/scitranslmed.3009587
Wu, Q. et al. Cancer-associated adipocytes: Key players in breast cancer progression. J. Hematol. Oncol. 12, 1–15 (2019).
doi: 10.1186/s13045-019-0778-6
Bao, X., Anastasov, N., Wang, Y. & Rosemann, M. A novel epigenetic signature for overall survival prediction in patients with breast cancer. J. Transl. Med. 17, 1–12 (2019).
doi: 10.1186/s12967-019-2126-6
Fouad, Y. A. & Aanei, C. Revisiting the hallmarks of cancer. Am. J. Cancer Res. 7, 1016 (2017).
pubmed: 28560055
pmcid: 5446472
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646–674 (2011).
pubmed: 21376230
doi: 10.1016/j.cell.2011.02.013
Aran, D. et al. Comprehensive analysis of normal adjacent to tumor transcriptomes. Nat. Commun. 8, 1–14 (2017).
doi: 10.1038/s41467-017-01027-z
Graham, K. et al. Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile. Br. J. Cancer 102, 1284–1293 (2010).
pubmed: 20197764
pmcid: 2855998
doi: 10.1038/sj.bjc.6605576
Kang, T. et al. A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population. Breast Cancer Res. 22, 1–15 (2020).
doi: 10.1186/s13058-020-01322-6
Román-Pérez, E. et al. Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients. Breast Cancer Res. 14, 1–12 (2012).
doi: 10.1186/bcr3152
Tripathi, A. et al. Gene expression abnormalities in histologically normal breast epithelium of breast cancer patients. Int. J. Cancer 122, 1557–1566 (2008).
pubmed: 18058819
doi: 10.1002/ijc.23267
Koudijs, K. K. M., Böhringer, S. & Guchelaar, H. J. Validation of transcriptome signature reversion for drug repurposing in oncology. Brief Bioinform. 24, bbac490 (2023).
pubmed: 36445193
doi: 10.1093/bib/bbac490
Borges, R. de P., Degobi, N. A. H. & Bertoluci, M. C. Choosing statins: A review to guide clinical practice. Arch. Endocrinol. Metab. 64, 639 (2020).
Torrandell-Haro, G. et al. Statin therapy and risk of Alzheimer’s and age-related neurodegenerative diseases. Alzheimer’s Dement. Transl. Res. Clin. Interv. 6, 149 (2020).
Yan, J. et al. Effect of statins on Parkinson’s disease: A systematic review and meta-analysis. Medicine (Baltimore) 98, e14852 (2019).
pubmed: 30896628
doi: 10.1097/MD.0000000000014852
Zhou, Q., Jiao, Z., Liu, Y., Devreotes, P. N. & Zhang, Z. The effects of statins in patients with advanced-stage cancers—A systematic review and meta-analysis. Front. Oncol. 13, 1234713 (2023).
pubmed: 37664034
pmcid: 10473877
doi: 10.3389/fonc.2023.1234713
Ahmadi, M. et al. Pleiotropic effects of statins: A focus on cancer. Biochim. Biophys. Acta Mol. Basis Dis. 1866, 1–17 (2020).
doi: 10.1016/j.bbadis.2020.165968
Borgquist, S., Bjarnadottir, O., Kimbung, S. & Ahern, T. P. Statins: A role in breast cancer therapy?. J. Intern. Med. 284, 346 (2018).
pubmed: 29923256
pmcid: 6175478
doi: 10.1111/joim.12806
Kumar, A. S. et al. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol. Biomark. Prev. 17, 1028–1033 (2008).
doi: 10.1158/1055-9965.EPI-07-0726
Desai, P. et al. Statins and breast cancer stage and mortality in the Women’s Health Initiative. Cancer Causes Control 26, 529–539 (2015).
pubmed: 25736184
pmcid: 5056588
doi: 10.1007/s10552-015-0530-7
Sun, L. et al. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer. Breast Cancer Res. 24, 1–10 (2022).
doi: 10.1186/s13058-022-01508-0
Kochhar, R., Khurana, V., Bejjanki, H., Caldito, G. & Fort, C. Statins to reduce breast cancer risk: A case control study in US female veterans. J. Clin. Oncol. 23, 514–514. https://doi.org/10.1200/jco.2005.23.16_suppl.514 (2005).
doi: 10.1200/jco.2005.23.16_suppl.514
Anothaisintawee, T. et al. Effect of lipophilic and hydrophilic statins on breast cancer risk in Thai women: A cross-sectional study. J. Cancer 7, 1163–1168 (2016).
pubmed: 27326260
pmcid: 4911884
doi: 10.7150/jca.14941
Wu, Q. J. et al. Statin use and breast cancer survival and risk: A systematic review and meta-analysis. Oncotarget 6, 42988 (2015).
pubmed: 26472026
pmcid: 4767486
doi: 10.18632/oncotarget.5557
Kim, S. et al. PubChem in 2021: New data content and improved web interfaces. Nucleic Acids Res. 49, D1388–D1395 (2021).
pubmed: 33151290
doi: 10.1093/nar/gkaa971
Sean, D. & Meltzer, P. S. GEOquery: A bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics 23, 1846–1847 (2007).
doi: 10.1093/bioinformatics/btm254
Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The SVA package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882 (2012).
pubmed: 22257669
pmcid: 3307112
doi: 10.1093/bioinformatics/bts034
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
pubmed: 25605792
pmcid: 4402510
doi: 10.1093/nar/gkv007
Szklarczyk, D. et al. The STRING database in 2023: Protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 51, D638–D646 (2023).
pubmed: 36370105
doi: 10.1093/nar/gkac1000
Tang, Z., Kang, B., Li, C., Chen, T. & Zhang, Z. GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 47, W556–W560 (2019).
pubmed: 31114875
pmcid: 6602440
doi: 10.1093/nar/gkz430
Lonsdale, J. et al. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45, 580–585 (2013).
doi: 10.1038/ng.2653
Weinstein, J. N. et al. The cancer genome atlas pan-cancer analysis project. Nat. Genet. 45, 1113 (2013).
pubmed: 24071849
pmcid: 3919969
doi: 10.1038/ng.2764
Xie, Z. et al. Gene set knowledge discovery with enrichr. Curr. Protoc. 1, e90 (2021).
pubmed: 33780170
pmcid: 8152575
doi: 10.1002/cpz1.90
Liberzon, A. et al. The molecular signatures database hallmark gene set collection. Cell Syst. 1, 417–425 (2015).
pubmed: 26771021
pmcid: 4707969
doi: 10.1016/j.cels.2015.12.004
Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51, D587–D592 (2023).
pubmed: 36300620
doi: 10.1093/nar/gkac963
Carbon, S. et al. The Gene Ontology Resource: 20 years and still GOing strong. Nucleic Acids Res. 47, D330–D338 (2019).
doi: 10.1093/nar/gky1055
Lachmann, A., Xie, Z. & Ma’ayan, A. blitzGSEA: Efficient computation of gene set enrichment analysis through gamma distribution approximation. Bioinformatics 38, 2356–2357 (2022).
pubmed: 35143610
pmcid: 9004650
doi: 10.1093/bioinformatics/btac076
Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453–457 (2015).
pubmed: 25822800
pmcid: 4739640
doi: 10.1038/nmeth.3337
Chen, B., Khodadoust, M. S., Liu, C. L., Newman, A. M. & Alizadeh, A. A. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol. Biol. 1711, 243 (2018).
pubmed: 29344893
pmcid: 5895181
doi: 10.1007/978-1-4939-7493-1_12
Gao, J. et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Sci. Signal. 6, pl1 (2013).
pubmed: 23550210
pmcid: 4160307
doi: 10.1126/scisignal.2004088
Chandrashekar, D. S. et al. UALCAN: An update to the integrated cancer data analysis platform. Neoplasia 25, 18–27 (2022).
pubmed: 35078134
pmcid: 8788199
doi: 10.1016/j.neo.2022.01.001
Jézéquel, P. et al. Bc-GenExMiner: An easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res. Treat. 131, 765–775 (2012).
pubmed: 21452023
doi: 10.1007/s10549-011-1457-7
Da Motta, L. L. et al. The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer. Oncogene 36, 122–132 (2016).
pubmed: 27292261
pmcid: 5061082
doi: 10.1038/onc.2016.184
Parikh, N. et al. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types. J. Pathol. 232, 522–533 (2014).
pubmed: 24374933
pmcid: 4362779
doi: 10.1002/path.4321
Kleivi, K. et al. TP53 mutations are associated with a particular pattern of genomic imbalances in breast carcinomas. J. Pathol. 207, 14–19 (2005).
pubmed: 16007576
doi: 10.1002/path.1812
Bertoli, C., Skotheim, J. M. & De Bruin, R. A. M. Control of cell cycle transcription during G1 and S phases. Nat. Rev. Mol. Cell Biol. 14, 518–528 (2013).
pubmed: 23877564
pmcid: 4569015
doi: 10.1038/nrm3629
Nieto, M. A., Huang, R. Y. Y. J., Jackson, R. A. A. & Thiery, J. P. P. EMT: 2016. Cell 166, 21–45 (2016).
pubmed: 27368099
doi: 10.1016/j.cell.2016.06.028
Hynes, R. O. The extracellular matrix: Not just pretty fibrils. Science (80-.) 326, 1216–1219 (2009).
doi: 10.1126/science.1176009
Gazzerro, P. et al. Pharmacological actions of statins: A critical appraisal in the management of cancer. Pharmacol. Rev. 64, 102–146 (2012).
pubmed: 22106090
doi: 10.1124/pr.111.004994